Centhaquine

DRUG4 trials

Sponsors

Pharmazz, Inc.

Conditions

Acute Respiratory Distress Syndrome (ARDS)Blood LossHypovolemic Shock

Phase 2

PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

CompletedNCT04056065

Pharmazz, Inc.Blood Loss, Hypovolemic Shock

Start: 2017-05-29End: 2018-10-21Updated: 2019-08-14

Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS

Not yet recruitingNCT05241067

Pharmazz, Inc.Acute Respiratory Distress Syndrome (ARDS)

Start: 2027-05-01End: 2027-12-31Target: 80Updated: 2026-09-17

Phase 3

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

Not yet recruitingNCT05251181

Pharmazz, Inc.Hypovolemic Shock

Start: 2027-02-01End: 2028-10-01Target: 430Updated: 2026-09-17

Phase 4

A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients

RecruitingNCT05956418

Pharmazz, Inc.Hypovolemic Shock

Start: 2021-08-13End: 2027-02-01Target: 400Updated: 2026-09-17

Related Papers

Centhaquine Increases Stroke Volume and Cardiac Output in Patients with Hypovolemic Shock

Journal of Clinical Medicine2024-06-273 citations

A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients

Drugs2021-06-0119 citations

Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial

Advances in Therapy2021-05-1016 citations

Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia

Frontiers in Pharmacology2021-05-0314 citations

Abstract 278: A Novel Resuscitative Agent, Centhaquine (Lyfaquin®), has the Potential to Treat Acute Kidney Injury Following Hemorrhagic Shock

Circulation2020-11-09